Oryzon Gains New Patents In Canada And Israel For CNS Drug Vafidemstat

Oryzon Genomics, a leader in epigenetic therapies, has received official “Decision to grant” notifications from the Canadian and Israeli patent offices for its applications concerning the use of its LSD1 inhibitor, vafidemstat. These patents covering the treatment of behavioral symptoms such as aggression and social withdrawal support the company’s ongoing development of vafidemstat for central nervous system (CNS) disorders.

“These patent allowances in Canada and Israel complement the robust portfolio we’ve already secured for vafidemstat, further strengthening our global IP position and supporting its commercial potential across multiple CNS indications”, said Neus Virgili, Oryzon’s Chief IP Officer

The newly approved patents strengthen Oryzon’s intellectual property portfolio, offering protection until at least 2038, with potential extensions possible. These rights complement existing patents already secured in Europe, Australia, Russia, and several Asian countries. Vafidemstat is currently being evaluated in multiple clinical trials, including a planned Phase III trial in borderline personality disorder (BPD) and Phase II trials in autism spectrum disorder (ASD) and schizophrenia.

In addition to this patent family, Oryzon holds broader rights on vafidemstat’s application to CNS disorders. A second patent group targeting BPD and its non-aggressive symptoms has been granted in several global markets, with protection lasting until at least 2040. These growing patent assets reinforce Oryzon’s strategic positioning in neuropsychiatric drug development.